Literature DB >> 33106934

Comparing in vitro human liver models to in vivo human liver using RNA-Seq.

Rajinder Gupta1, Yannick Schrooders1, Duncan Hauser1, Marcel van Herwijnen1, Wiebke Albrecht2, Bas Ter Braak3, Tim Brecklinghaus2, Jose V Castell4, Leroy Elenschneider5, Sylvia Escher5, Patrick Guye6, Jan G Hengstler2, Ahmed Ghallab2,7, Tanja Hansen5, Marcel Leist8, Richard Maclennan9, Wolfgang Moritz6, Laia Tolosa10, Tine Tricot11, Catherine Verfaillie11, Paul Walker9, Bob van de Water3, Jos Kleinjans1, Florian Caiment12.   

Abstract

The liver plays an important role in xenobiotic metabolism and represents a primary target for toxic substances. Many different in vitro cell models have been developed in the past decades. In this study, we used RNA-sequencing (RNA-Seq) to analyze the following human in vitro liver cell models in comparison to human liver tissue: cancer-derived cell lines (HepG2, HepaRG 3D), induced pluripotent stem cell-derived hepatocyte-like cells (iPSC-HLCs), cancerous human liver-derived assays (hPCLiS, human precision cut liver slices), non-cancerous human liver-derived assays (PHH, primary human hepatocytes) and 3D liver microtissues. First, using CellNet, we analyzed whether these liver in vitro cell models were indeed classified as liver, based on their baseline expression profile and gene regulatory networks (GRN). More comprehensive analyses using non-differentially expressed genes (non-DEGs) and differential transcript usage (DTU) were applied to assess the coverage for important liver pathways. Through different analyses, we noticed that 3D liver microtissues exhibited a high similarity with in vivo liver, in terms of CellNet (C/T score: 0.98), non-DEGs (10,363) and pathway coverage (highest for 19 out of 20 liver specific pathways shown) at the beginning of the incubation period (0 h) followed by a decrease during long-term incubation for 168 and 336 h. PHH also showed a high degree of similarity with human liver tissue and allowed stable conditions for a short-term cultivation period of 24 h. Using the same metrics, HepG2 cells illustrated the lowest similarity (C/T: 0.51, non-DEGs: 5623, and pathways coverage: least for 7 out of 20) with human liver tissue. The HepG2 are widely used in hepatotoxicity studies, however, due to their lower similarity, they should be used with caution. HepaRG models, iPSC-HLCs, and hPCLiS ranged clearly behind microtissues and PHH but showed higher similarity to human liver tissue than HepG2 cells. In conclusion, this study offers a resource of RNA-Seq data of several biological replicates of human liver cell models in vitro compared to human liver tissue.

Entities:  

Keywords:  CellNet; In vitro liver; In vivo liver; Non-DEGs; Non-DEGsDTU−; Pathway coverage; RNA-seq

Year:  2020        PMID: 33106934      PMCID: PMC7870774          DOI: 10.1007/s00204-020-02937-6

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  19 in total

1.  Two rare causes of portal hypertension: the importance of establishing the cause.

Authors:  L A Rigberg
Journal:  Ariz Med       Date:  1978-08

2.  RNA sequencing: platform selection, experimental design, and data interpretation.

Authors:  Yongjun Chu; David R Corey
Journal:  Nucleic Acid Ther       Date:  2012-07-25       Impact factor: 5.486

3.  Fast gapped-read alignment with Bowtie 2.

Authors:  Ben Langmead; Steven L Salzberg
Journal:  Nat Methods       Date:  2012-03-04       Impact factor: 28.547

Review 4.  The endoplasmic reticulum in xenobiotic toxicity.

Authors:  Alastair E Cribb; Mathieu Peyrou; Shanmugam Muruganandan; Laetitia Schneider
Journal:  Drug Metab Rev       Date:  2005       Impact factor: 4.518

5.  A brief history of animal modeling.

Authors:  Aaron C Ericsson; Marcus J Crim; Craig L Franklin
Journal:  Mo Med       Date:  2013 May-Jun

6.  HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans.

Authors:  Kajsa P Kanebratt; Tommy B Andersson
Journal:  Drug Metab Dispos       Date:  2007-10-22       Impact factor: 3.922

7.  Of mice and men: the evolution of animal welfare guidelines for cancer research.

Authors:  N Dey; P De; B R Smith; B Leyland-Jones
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

8.  The impact of read length on quantification of differentially expressed genes and splice junction detection.

Authors:  Sagar Chhangawala; Gabe Rudy; Christopher E Mason; Jeffrey A Rosenfeld
Journal:  Genome Biol       Date:  2015-06-23       Impact factor: 13.583

9.  CellNet: network biology applied to stem cell engineering.

Authors:  Patrick Cahan; Hu Li; Samantha A Morris; Edroaldo Lummertz da Rocha; George Q Daley; James J Collins
Journal:  Cell       Date:  2014-08-14       Impact factor: 41.582

10.  The Ensembl gene annotation system.

Authors:  Bronwen L Aken; Sarah Ayling; Daniel Barrell; Laura Clarke; Valery Curwen; Susan Fairley; Julio Fernandez Banet; Konstantinos Billis; Carlos García Girón; Thibaut Hourlier; Kevin Howe; Andreas Kähäri; Felix Kokocinski; Fergal J Martin; Daniel N Murphy; Rishi Nag; Magali Ruffier; Michael Schuster; Y Amy Tang; Jan-Hinnerk Vogel; Simon White; Amonida Zadissa; Paul Flicek; Stephen M J Searle
Journal:  Database (Oxford)       Date:  2016-06-23       Impact factor: 3.451

View more
  12 in total

1.  HIV- 1 lentivirus tethering to the genome is associated with transcription factor binding sites found in genes that favour virus survival.

Authors:  Saqlain Suleman; Annette Payne; Johnathan Bowden; Sharmin Al Haque; Marco Zahn; Serena Fawaz; Mohammad S Khalifa; Susan Jobling; David Hay; Matteo Franco; Raffaele Fronza; Wei Wang; Olga Strobel-Freidekind; Annette Deichmann; Yasuhiro Takeuchi; Simon N Waddington; Irene Gil-Farina; Manfred Schmidt; Michael Themis
Journal:  Gene Ther       Date:  2022-05-05       Impact factor: 5.250

2.  Lipidomics profiles in hepatocytes from nonalcoholic steatohepatitis patients differ markedly from in vitro-induced steatotic hepatocytes.

Authors:  Thomas Kralj; Raju Khatri; Kenneth R Brouwer; Kim L R Brouwer; Darren J Creek
Journal:  FEBS Lett       Date:  2022-02-28       Impact factor: 3.864

Review 3.  Advancements in Disease Modeling and Drug Discovery Using iPSC-Derived Hepatocyte-like Cells.

Authors:  Josef Blaszkiewicz; Stephen A Duncan
Journal:  Genes (Basel)       Date:  2022-03-24       Impact factor: 4.141

4.  Plasma miR-193b-3p Is Elevated in Type 2 Diabetes and Could Impair Glucose Metabolism.

Authors:  Hua Hu; Meng Zhao; Zhaoyang Li; Hongli Nie; Jia He; Zhuo Chen; Jing Yuan; Huan Guo; Xiaomin Zhang; Handong Yang; Tangchun Wu; Meian He
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-27       Impact factor: 6.055

5.  Single Cell Gene Expression Analysis in a 3D Microtissue Liver Model Reveals Cell Type-Specific Responses to Pro-Fibrotic TGF-β1 Stimulation.

Authors:  Catherine Jane Messner; Lmar Babrak; Gaia Titolo; Michaela Caj; Enkelejda Miho; Laura Suter-Dick
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

Review 6.  The Curious Case of the HepG2 Cell Line: 40 Years of Expertise.

Authors:  Viktoriia A Arzumanian; Olga I Kiseleva; Ekaterina V Poverennaya
Journal:  Int J Mol Sci       Date:  2021-12-04       Impact factor: 5.923

7.  HepG2-Based Designer Cells with Heat-Inducible Enhanced Liver Functions.

Authors:  Hiroyuki Kitano; Yoshinori Kawabe; Masamichi Kamihira
Journal:  Cells       Date:  2022-04-01       Impact factor: 6.600

8.  TIA1 Loss Exacerbates Fatty Liver Disease but Exerts a Dual Role in Hepatocarcinogenesis.

Authors:  Dobrochna Dolicka; Szabolcs Zahoran; Marta Correia de Sousa; Monika Gjorgjieva; Christine Sempoux; Margot Fournier; Christine Maeder; Martine A Collart; Michelangelo Foti; Cyril Sobolewski
Journal:  Cancers (Basel)       Date:  2022-03-27       Impact factor: 6.639

Review 9.  Research and Development of Microphysiological Systems in Japan Supported by the AMED-MPS Project.

Authors:  Seiichi Ishida
Journal:  Front Toxicol       Date:  2021-04-29

Review 10.  Modelling urea cycle disorders using iPSCs.

Authors:  Claire Duff; Julien Baruteau
Journal:  NPJ Regen Med       Date:  2022-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.